160 related articles for article (PubMed ID: 34986845)
1. RRM2 expression in different molecular subtypes of breast cancer and its prognostic significance.
Abdel-Rahman MA; Mahfouz M; Habashy HO
Diagn Pathol; 2022 Jan; 17(1):1. PubMed ID: 34986845
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers.
Zhang H; Liu X; Warden CD; Huang Y; Loera S; Xue L; Zhang S; Chu P; Zheng S; Yen Y
BMC Cancer; 2014 Sep; 14():664. PubMed ID: 25213022
[TBL] [Abstract][Full Text] [Related]
3. High expression of ribonucleotide reductase subunit M2 correlates with poor prognosis of hepatocellular carcinoma.
Lee B; Ha SY; Song DH; Lee HW; Cho SY; Park CK
Gut Liver; 2014 Nov; 8(6):662-8. PubMed ID: 25368754
[TBL] [Abstract][Full Text] [Related]
4. Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance.
Putluri N; Maity S; Kommagani R; Creighton CJ; Putluri V; Chen F; Nanda S; Bhowmik SK; Terunuma A; Dorsey T; Nardone A; Fu X; Shaw C; Sarkar TR; Schiff R; Lydon JP; O'Malley BW; Ambs S; Das GM; Michailidis G; Sreekumar A
Neoplasia; 2014 May; 16(5):390-402. PubMed ID: 25016594
[TBL] [Abstract][Full Text] [Related]
5. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
Fisher SB; Fisher KE; Patel SH; Lim MG; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Farris AB; Maithel SK
Cancer; 2013 Jan; 119(2):454-62. PubMed ID: 22760605
[TBL] [Abstract][Full Text] [Related]
6. Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.
Grossi F; Dal Bello MG; Salvi S; Puzone R; Pfeffer U; Fontana V; Alama A; Rijavec E; Barletta G; Genova C; Sini C; Ratto GB; Taviani M; Truini M; Merlo DF
Dis Markers; 2015; 2015():302649. PubMed ID: 26663950
[TBL] [Abstract][Full Text] [Related]
7. Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma.
Han P; Lin ZR; Xu LH; Zhong Q; Zhu XF; Liang FY; Cai Q; Huang XM; Zeng MS
Mol Med Rep; 2015 Jul; 12(1):401-9. PubMed ID: 25695839
[TBL] [Abstract][Full Text] [Related]
8. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment.
Fisher SB; Patel SH; Bagci P; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Maithel SK
Cancer; 2013 Jan; 119(2):445-53. PubMed ID: 22569992
[TBL] [Abstract][Full Text] [Related]
9. Bioinformatics analysis revealing prognostic significance of
Chen WX; Yang LG; Xu LY; Cheng L; Qian Q; Sun L; Zhu YL
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30898978
[No Abstract] [Full Text] [Related]
10. Comprehensive bioinformatics analysis of ribonucleoside diphosphate reductase subunit M2(RRM2) gene correlates with prognosis and tumor immunotherapy in pan-cancer.
Wu L; Yin L; Ma L; Yang J; Yang F; Sun B; Nianzeng X
Aging (Albany NY); 2022 Oct; 14(19):7890-7905. PubMed ID: 36202136
[TBL] [Abstract][Full Text] [Related]
11. The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients.
Su YF; Wu TF; Ko JL; Tsai HT; Tee YT; Chien MH; Chou CH; Lin WL; Low HY; Chou MY; Yang SF; Wang PH
PLoS One; 2014; 9(3):e91644. PubMed ID: 24637958
[TBL] [Abstract][Full Text] [Related]
12. DSCAM-AS1 promotes tumor growth of breast cancer by reducing miR-204-5p and up-regulating RRM2.
Liang WH; Li N; Yuan ZQ; Qian XL; Wang ZH
Mol Carcinog; 2019 Apr; 58(4):461-473. PubMed ID: 30457164
[TBL] [Abstract][Full Text] [Related]
13. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
Huang Y; Liu X; Wang YH; Yeh SD; Chen CL; Nelson RA; Chu P; Wilson T; Yen Y
Urol Oncol; 2014 Jan; 32(1):51.e9-19. PubMed ID: 24360663
[TBL] [Abstract][Full Text] [Related]
15. A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2).
Mazzu YZ; Armenia J; Chakraborty G; Yoshikawa Y; Coggins SA; Nandakumar S; Gerke TA; Pomerantz MM; Qiu X; Zhao H; Atiq M; Khan N; Komura K; Lee GM; Fine SW; Bell C; O'Connor E; Long HW; Freedman ML; Kim B; Kantoff PW
Clin Cancer Res; 2019 Jul; 25(14):4480-4492. PubMed ID: 30996073
[TBL] [Abstract][Full Text] [Related]
16. Ribonucleotide reductase subunit M2 predicts survival in subgroups of patients with non-small cell lung carcinoma: effects of gender and smoking status.
Mah V; Alavi M; Márquez-Garbán DC; Maresh EL; Kim SR; Horvath S; Bagryanova L; Huerta-Yepez S; Chia D; Pietras R; Goodglick L
PLoS One; 2015; 10(5):e0127600. PubMed ID: 26001082
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of catalytic subunit M2 in patients with ovarian cancer.
Wang LM; Lu FF; Zhang SY; Yao RY; Xing XM; Wei ZM
Chin Med J (Engl); 2012 Jun; 125(12):2151-6. PubMed ID: 22884145
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and Immunological Potential of Ribonucleotide Reductase Subunits in Liver Cancer.
Yin X; Jiang K; Zhou Z; Yu H; Yan D; He X; Yan S
Oxid Med Cell Longev; 2023; 2023():3878796. PubMed ID: 36713030
[TBL] [Abstract][Full Text] [Related]
19. The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors.
Goss KL; Koppenhafer SL; Waters T; Terry WW; Wen KK; Wu M; Ostergaard J; Gordon PM; Gordon DJ
Oncogene; 2021 Jan; 40(3):564-577. PubMed ID: 33191406
[TBL] [Abstract][Full Text] [Related]
20. Cell-cycle-dependent phosphorylation of RRM1 ensures efficient DNA replication and regulates cancer vulnerability to ATR inhibition.
Shu Z; Li Z; Huang H; Chen Y; Fan J; Yu L; Wu Z; Tian L; Qi Q; Peng S; Wei C; Xie Z; Li X; Feng Q; Sheng H; Li G; Wei D; Shan C; Chen G
Oncogene; 2020 Aug; 39(35):5721-5733. PubMed ID: 32712628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
